Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Müller, N. Articles by Schwarz, M. J. Search for Related Content PubMed Citation Articles by Müller, N. Articles by Schwarz, M. J. Schizophrenia Spectrum Disorders Other Somatic Therapy Other Neuroleptics

Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia

OBJECTIVE: Abnormalities in the immune system in schizophrenia have been described. However, important findings such as high levels of activating cytokines in the CSF and signs of CNS inflammation have been controversial. The authors conducted a trial of the new selective cyclooxygenase-2 inhibitor celecoxib, an immunomodulatory drug, in schizophrenic patients to evaluate its therapeutic effects. METHOD: In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo. After a washout period, 25 patients received 2–6 mg/day of risperidone plus placebo and 25 received risperidone plus 400 mg/day of celecoxib for 5 weeks. The treatment effect was calculated by analysis of covariance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or risperidone dose or plasma level. RESULTS: Over 5 weeks, both groups of patients showed significant improvement in scores on the Positive and Negative Syndrome Scale and on all subscales. However, the celecoxib group showed significantly greater improvement in the total score. CONCLUSIONS: Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology. Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder. However, a nonimmunological therapeutic effect of celecoxib mediated by the N-methyl-D-aspartic acid receptor has to be taken into account.

This article has been cited by other articles:

				M. Mizuno, H. Sotoyama, E. Narita, H. Kawamura, H. Namba, Y. Zheng, T. Eda, and H. Nawa A Cyclooxygenase-2 Inhibitor Ameliorates Behavioral Impairments Induced by Striatal Administration of Epidermal Growth Factor J. Neurosci., September 19, 2007; 27(38): 10116 - 10127. [Abstract] [Full Text] [PDF]

				M. Tenenbaum, A. N. Azab, and J. Kaplanski Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures Innate Immunity, June 1, 2007; 13(3): 158 - 166. [Abstract] [PDF]

				M. Murnaghan, G. Li, and D. R. Marsh Nonsteroidal Anti-Inflammatory Drug-Induced Fracture Nonunion: An Inhibition of Angiogenesis? J. Bone Joint Surg. Am., November 1, 2006; 88(suppl_3): 140 - 147. [Abstract] [Full Text] [PDF]

				M Hellstrand, E A Danielsen, V M Steen, A Ekman, E Eriksson, and C L Nilsson The ser9gly SNP in the dopamine D3 receptor causes a shift from cAMP related to PGE2 related signal transduction mechanisms in transfected CHO cells J. Med. Genet., November 1, 2004; 41(11): 867 - 871. [Full Text] [PDF]

				Can COX-2 Inhibitors Help to Treat Schizophrenia? Journal Watch Psychiatry, July 24, 2002; 2002(724): 7 - 7. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us